Nimisha A. Patel, M.D.
Department of Head and Neck Surgery, Division of Surgery
Present Title & Affiliation
Primary Appointment
Associate Patient Safety Quality Officer, Department of Head and Neck Surgery, Section of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX
Lead Ophthalmologist for Clinical Research Trials, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 1992 | New York University School of Medicine, New York, New York, US, Medicine, MD |
| 1988 | Stony Brook University, Stony Brook, New York, US, Biochemistry, BS |
Postgraduate Training
| 1996-1997 | Clinical Fellowship, Glaucoma, Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas |
| 1993-1996 | Clinical Residency, Ophthalmology, New York University Medical Center, New York, New York |
| 1992-1993 | Clinical Internship, General/Internal Medicine, School of Medicine at Stony Brook, Stony Brook, New York |
Licenses & Certifications
| 1998 | American Board of Ophthalmology |
| 1996 | Texas Medical Board |
Experience & Service
Administrative Appointments/Responsibilities
Medical records committee, Department Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present
Associate patient safety and quality officer, Department of Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - Present
Ophthalmology Lead for research clinical trials, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - Present
Other Professional Positions
Clinical Specialist, Ophthalmology, UT MDA CC, Houston, TX, 2014 - 2020
Director and Owner, Ophthalmology, Eye Health & Surgical Care, PLLC, Houston, TX, 2009 - 2020
Consultant - Glaucoma Specialist, Ophthalmology, San Jacinto Methodist Hospital, Baytown, Texas, 2007 - 2008
Consultant - Glaucoma specialist, Ophthalmology, Eye Surgery of Texas, Plano, TX, 2005 - 2009
Associate Glaucoma Specialist, Ophthalmology, Surgical Eye Associates, Houston, TX, 2003 - 2005
Associate Glaucoma Specialist, Ophthalmology, Midwest Eye Center, Cinncinati, Ohio, 1998 - 2002
Associate Glaucoma Specialist, Ophthalmology, Memorial Eye Institute, Harrisburg, Pennsylvania, 1998 - 1998
Intramural Institutional Committee Activities
Member - Head and Neck Surgery, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Honors & Awards
| 1991 | Rudin Foundation Scholarship, School of Medicine, New York University |
| 1989 | Fellowship, Honors in Anatomy, School of Medicine, New York University |
| 1989 | Wolf Scholarship, School of Medicine, New York University |
| 1988 | Honors Graduate, Biochemistry, State University of New York |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Erdafitinib (Pan FGFR-kinase inhibitor). Invited. Ophthalmology Grand Rounds and M&M Meeting. Houston, Texas, US.
- 2025. Antibody drug Conjugates – Ocular side effects – A closer look. Invited. Ophthalmology Grand Rounds and M&M Meeting. Houston, Texas, US.
- 2025. Case Report - Management of ADC Grade 3 Adverse event. Invited. Ophthalmology Grand Rounds and M&M Meeting. Houston, Texas, US.
- 2024. Unraveling the mystery of "Protocol CLinic". Invited. Ophthalmology Grand Rounds and M&M Meeting. Houston, Texas, US.
- 2010. Diabetic Retinopathy and Blood Glucose control. Invited. Memorial Hermann Patient Education Series. Houston, Texas, US.
- 1999. Glaucoma - A new Prespective. Invited. Cincinnati, Ohio, US.
- 1997. Spontaneous Choroidal Effusions in PAtients with Idiopathic Dilated Episcleral Vessels. Texas Ophthalmology Association. Houston, Texas, US.
- 1993. Therapy for Blepharospasm using Calcium Channel Blockers. Annual Meeting. New York, NY, US.
National Presentations
- 2023. Discussion on ocular events with ADCs 3. “Practical strategies for implementing updates Blenrep REMS in your practice. Invited. Ophthalmological Consult for ocular toxicity in prep for Theratechnologies' Scientific Advisory Committee. Houston, Texas, US.
- 2022. Overview of Corneal Toxicity and Challenges in monitoring during early drug development- Part 2. Invited. Ocular Toxicity Mini Symposium- FDA for Office of Oncologic Diseases and the Oncology Center of Excellence, US.
- 2022. Overview of Corneal Toxicity and Challenges in the Monitoring During Early Drug Development- Part 1. Invited. Ocular Toxicity Mini Symposium- FDA for Office of Oncologic Diseases and the Oncology Center of Excellence. Houston, Texas, US.
- 2021. Podium Presentation: Highlights on Ocular Adverse Effects of Checkpoint Inhibitor Immunotherapy at US Tertiary Cancer Center. Conference. Podium Presentation: Highlights on Ocular Adverse Effects of Checkpoint Inhibitor Immunotherapy at US Tertiary Cancer Center. New Orleans, LA, US.
- 2020. Ocular Toxicity Profile of Targeted Cancer Therapy at a US Tertiary Cancer Center. Poster. Ocular Toxicity Profile of Targeted Cancer Therapy at a US Tertiary Cancer Center, US.
- 1997. Legal Blindness in Primary Open Angle Glaucoma. Conference. Legal Blindness in Primary Open Angle Glaucoma. Fort Lauderdale, FL, US.
- 1997. Combined Procedures – Same site vs. Separate Incision. Conference. Combined Procedures – Same site vs. Separate Incision. Fort Lauderdale, FL, US.
- 1997. Demographic and Systemic Variable in Glaucoma Suspects. Conference. Demographic and Systemic Variable in Glaucoma Suspects. Fort Lauderdale, FL, US.
- 1996. PMMA Lenses used it Identify Decreased Visual. Conference. PMMA Lenses used it Identify Decreased Visual. Las Vegas, NV, US.
Formal Peers
- 2025. Ocular Monitoring and Management Education Consultation, US.
- 2024. Eye Care Professional (ECP) Advisory Council for belantamab mafodotin. Houston, Texas, US.
- 2022. Educate other institutions on the setup of clinical research focused ophthalmology clinics and diagnostic imaging. Houston, Texas, US.
- 2020. Blenrep related ocular toxicity. Houston, Texas, US.
- 1999. Glaucoma: A new Perspective. Invited. Cincinnati, OH, US.
- 1997. Spontaneous Choroidal Effusions in Patient with Idiopathic Dilated Episcleral vessels. Invited. Dallas, TX, US.
Grant & Contract Support
| Date: | 1996 |
| Title: | PMMA Lens used to Identify Decreased Vision |
| Funding Source: | Contact Lens Association of Ophthalmology (CLAO) |
| Role: | Recipient |
| ID: | Young Investigators Research Grant |
Selected Publications
Peer-Reviewed Articles
- Farbowitz, Furst H, Kastner, Patel, N, Jacoby, J. Effects of Diltiazem on lid tension during light flash induced eye blinks in the rabbit. Investigative Ophthalmology and Visual Sciences, 1993. e-Pub 1993.
- Scott SA, Patel N, Levin JM. Lectin binding identifies a Subpopulation of Neurons in Chick. Journal of Neurosciences, 1990. e-Pub 1990.
Invited Articles
- Joud Hajjar, Stephen B, Aaroe AE, Aiche MM, Al-Zubidi N, MayAmeri, Brooks KA, Carabenciov ID, Chambers MS, Chaudhry AL, Connors JM, Davies MA, Debnath KC, Faiz SA, Fuller CD, Goepfert RP, Gombos DS, Gupta S, Hadfield M, Hutcheson KA, Islam S, Jalal A, Jayasekara M, Jazieh KA, Khine A, Kim P, Lai SY, Lei YL, Li YJ, Markovic SN, McMillan H, Moreno AC, Muhaj F, Nader M, Otun A, Pacha O, Palaskas NL, Patel AB, Patel N, Quandt Z, Sagiv O, Sharon E, Shatila M, Sheshadri A, SuarezAlmazor ME, Thomas AS, Wang Y, Won A, Zhang HC, Aung, Naing. Immune Checkpoint Inhibitors: From Promise to Plateau—How Toxicity, Resistance, and Biomarker Gaps Shaped Outcomes, and Strategies to Overcome Them. Journal of Immunotherapy and Precision Oncology. e-Pub 2026.
Abstracts
- Ameri, M, Al-Zubidi, N, Razmandi, A, Whyte, A, Naing, A, Patel, N, Gombos, DS. Ocular toxicity profile of targeted cancer therapy at a US tertiary care center. Cureus 15, 2023. e-Pub 2023. PMID: 37347077.
- Mazharuddin AA, Whyte AT, Gombos DS, Patel N, Razmandi A, Chaudhry AL, Al-Zubidi NS. Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center. J Immunother Precis Oncol 5(4):98-104, 2022. e-Pub 2022. PMID: 36483585.
- Melody Becnel, Ferreri, Christopher J, Feng, Lei, Richards, Tiffany, Horowitz, Sandra B, Patel, Nimisha, Gombos, Dan S, Razmandi, Azadeh, Murga, Astrid, Seif, Sherif, Youssef, George, Murphy, Kevin, Kaufman, Gregory Peter, Weber, Donna M, Patel, Krina K, Thomas, Sheeba K, Manasanch, Elisabeth Esteve, Orlowski, Robert Z., Lee, Hans C. Retrospective, single-center, real-world experience of belantamab mafodotin in relapsed/refractory multiple myeloma. Journal of Clinical Oncology Volume 40(Number 16), 2022. e-Pub 2022.
- Abbasoglu, OH, Kooru, KS, Patel, N. Combined phacoemulsificaton and trabeculectomy with mitomycin-C; SA vie versus different sites. Investigative Ophthalmology and Visual Science 38(4):S265, 1997. e-Pub 1997.
- Nimisha Patel. MRD-Guided Maintenance Therapy with Belantamab Mafodotin and Lenalidomide After Auto-HCT in Newly Diagnosed Multiple Myeloma: Interim Analysis. European Hematology Association.
Patient Reviews
CV information above last modified July 22, 2026